Have you or your loved ones been diagnosed with chronic prostatitis with chronic pelvic pain syndrome?

You may be eligible to participate in a chronic prostatitis with chronic pelvic pain syndrome clinical trial.

Have you or your loved ones been diagnosed with chronic prostatitis with chronic pelvic pain syndrome? You may be eligible to participate in a chronic prostatitis with chronic pelvic pain syndrome clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Chronic Prostatitis With Chronic Pelvic Pain Syndrome Clinical Trial in Beijing Beijing

NCT03213938 | Interventional

Have you or your loved ones been diagnosed with chronic prostatitis with chronic pelvic pain syndrome?

You may be eligible to participate in a chronic prostatitis with chronic pelvic pain syndrome clinical trial.

Completed

Male

18 - 50

Years old

This study has recruited 440 Participants

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refers to the presence of bothersome pelvic pain symptoms without an identifiable cause. Common symptoms of CP/CPPS include discomfort in the perineum, suprapubic region, and lower urinary tract symptoms. It affects men of all ages without apparent racial predisposition, among which, 36-50 years old are the most commonly influenced. Yet, few effective therapies are available for treating CP/CPPS. Acupuncture may be an effective treatment option for CP/CPPS. However, effects of acupuncture on CP/CPPS remain uncertain because of the small sample sizes or other methodological limitations. The objective of this multi-centre, randomized, sham acupuncture-controlled trial is to assess the effectiveness of acupuncture for relieving symptoms of CP/CPPS. The results will provide a robust conclusion with a high level of evidence.

Show me more details

Details for the study

Brief Title

Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Official Title

Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Multicenter Randomized Controlled Trial

Brief Summary

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refers to the presence of bothersome pelvic pain symptoms without an identifiable cause. Common symptoms of CP/CPPS include discomfort in the perineum, suprapubic region, and lower urinary tract symptoms. It affects men of all ages without apparent racial predisposition, among which, 36-50 years old are the most commonly influenced. Yet, few effective therapies are available for treating CP/CPPS. Acupuncture may be an effective treatment option for CP/CPPS. However, effects of acupuncture on CP/CPPS remain uncertain because of the small sample sizes or other methodological limitations. The objective of this multi-centre, randomized, sham acupuncture-controlled trial is to assess the effectiveness of acupuncture for relieving symptoms of CP/CPPS. The results will provide a robust conclusion with a high level of evidence.

Treatments and/or Procedures

Acupuncture

For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol. Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).

Sham acupuncture

For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35. Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.

Primary

Proportion of Responders at the End of 32-week

The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the NIH-CPSI.

week 32

Primary

Proportion of Responders at the End of 8-week

The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI).

week 8

Secondary

the Proportions of Participants in Each Response Category of the Global Response Assessment (GRA)

GRA consists of 7 response categories: markedly worsened, moderately worsened, slightly worsened, no change, slightly improved, moderately improved, and markedly improved.

week 4; week 8; week 20; week 32

Secondary

the Change From Baseline in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire

The EQ-5D-5L is a well-established and suitable for evaluation of quality of life in participants with CP/CPPS. EQ-5D-5L overall index ranges from -0.39 to 1.00, with higher overall index indicating better generic health-status.

week 8; week 20; week 32

Secondary

Proportion of Responders at Other Time Points

The responder is defined as who has a decline of 6 or more than 6-point from baseline measured by using the NIH-CPSI.

weeks 1-7; week 20

Secondary

the Change From Baseline in the Hospital Anxiety and Depression Scale (HADS)

HADS is made up of 7 items for the assessment of depression and anxiety; the completion of this scale usually requires 2-5 minutes. HADS score ranges from 0 to 42, with higher scores indicating greater anxiety and depression.

week 8; week 20; week 32

Secondary

the Change From Baseline in the International Prostate Symptom Score (IPSS)

IPSS is a valid, reliable and sensitive measure for patients with lower urinary tract symptoms; it is widely used in clinical practice and research to determine the severity of lower urinary tract symptoms, including incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine stream, straining and nocturia. Each of the questions is rated from 0 (not at all) to 5 (almost always). IPSS score ranges from 0 to 35, with higher score indicating more severe urinary symptoms.

week 4; week 8; week 20; week 32

Secondary

the Change From Baseline in NIH-CPSI Subscales

The NIH-CPSI is a universally accepted, reliable and valid instrument recommended for clinical evaluation and research of CP/CPPS by consensus guidelines. It measures the domains of pain, urinary function and quality of life impact in CP/CPPS. The score range of pain subscale is 0-21, with higher scores indicating worse conditions. The score range of urinary function subscale is 0-10, with higher scores indicating worse conditions. The score range of quality-of-life subscale is 0-12, with higher scores indicating worse quality of life.

weeks 1-8; week 20; week 32

Secondary

the Change From Baseline in NIH-CPSI Total Score

The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) is a universally accepted, reliable and valid instrument recommended for clinical evaluation and research of CP/CPPS by consensus guidelines. It measures the domains of pain (score range, 0-21), urinary function (0-10) and quality of life impact (0-12) in CP/CPPS, with a total score ranging from 0 to 43 and higher scores indicating worse conditions.

weeks 1-8; week 20; week 32

Secondary

the Change From Baseline in the International Index of Erectile Function 5 (IIEF-5)

The IIEF-5 is a psychometrically valid and reliable instrument with high sensitivity and specificity for detecting treatment effects in patients with erection dysfunction of a broad spectrum of aetiology. Chinese version IIEF-5 score ranges from 0 to 25, with lower scores indicating greater severity of dysfunction and minimal clinical important difference over 5.

week 8; week 20; week 32

Other

Expectation Assessment

Expectation assessment will be assessed at baseline, which includes 2 brief questions to investigate whether patients are confident that acupuncture treatment will help their CP/CPPS: "In general, is acupuncture effective for controlling the illness?", "Do you think acupuncture will helpful to improve your CP/CPPS symptoms?" For each question, participants could choose "Yes", "No" or "unclear" as the answer.

baseline

Study Criteria

Inclusion Criteria:
- 1.History of pain perceived in the prostate region and absence of other lower urinary
tract pathology for a minimum of three of the past 6 months. In addition, any
associated lower urinary tract symptoms, sexual function, and psychological factors
should be addressed. Physical examinations, urinary analyses, and urine cultures will
be performed for all subjects;
- 2. Age 18 to 50 years.
- 3. NIH Chronic Prostatitis Symptom Index (NIH- CPSI) total score ≥ 15.
Exclusion Criteria:
- 1. Prostate, bladder, or urethral cancer, seizure disorder in any medical history.
- 2. Inflammatory bowel disease, active urethral stricture, neurologic disease or
disorder affecting the bladder, liver disease, neurologic impairment or psychiatric
disorder preventing understanding of consent and self-report scale.
- 3. Urinary tract infection with a urine culture value of more than 100,000 CFU/mL,
clinical evidence of urethritis, including urethral discharge or positive culture,
diagnostic of sexually transmitted diseases (including gonorrhoea, chlamydia,
mycoplasma or trichomonas, but not including HIV/AIDS), symptoms of acute or chronic
epididymitis).
- 4. Residual urine volume≥100ML.
- 5. Qmax≤15ML/S.
- 6. Prior 4 weeks used androgen hormone inhibitors (finasteride), alpha-blockers
(terazosin HCI, doxazosin mesylate, tamsulosin hydrochloride), antibiotics
(ciprofloxacin hydrochloride), or any other prostatitis-specific medication (including
herb and Chinese medicine).